Pain

A small study found that ketamine decreased symptoms of depression—investigators studied its effects in combination with the opioid-blocker naltrexone compared to a placebo.

The director of Pain Management and Palliative Care at the Englewood Hospital & Medical Center in Englewood, NJ, explains how analgesics may come to the forefront of pain management care.

How issues with pain in patients with Lyme disease or opioid-induced constipation can be managed in a timely, efficient manner.

The SPRINT endura and extensa are cleared for both chronic and acute pain including post-operative pain and post-traumatic pain.

The 30-person panel, including physicians and patients, recommended a median 12.5 tablets of 5mg opioid for 20 common procedures.

A Denmark retrospective study of 7 million-plus individuals found associations between increased TBI severity and frequency, and suicide risk.

According to pooled data, 91.8% of the hospitalizations due to firearm injuries in pediatric and adolescent patients were of urban patients, 4.8% were of micropolitan patients, and 3.3% were of rural patients.

From 1999 to 2014, prevalence of opioid use disorder among women giving birth increased 333% nationally, according to a report from the Centers for Disease Control and Prevention.

How researchers are using stem cells and a greater patient population to improve on the invasive methods used to treat the common women's disease.

The FDA accepted the NDA for NKTR-181, a drug with slowed entry into the brain that attenuates the dopamine release underlying euphoria.

Elagolix (Orlissa) is the first oral gonadotropin-releasing hormone antagonist specifically developed for women with moderate to severe endometriosis pain.

The use of a single drop of nepafenac 0.3% suspension has shown in a trial to be an effective pain reducer post-intravitreal injection at both 6-hour and 24-hour points.

People of good conscience, including many physicians, are sharply divided on the ethics of MAID/PAS. Unfortunately, much of the support for this practice is founded on several myths and misconceptions regarding existing MAID laws and practices, according to Ronald Pies, MD.

Combined analysis of 2 prospective studies showed that marijuana use was associated with an increased risk for cough and sputum production.

Military veterans often pursue unique avenues towards a career in civilian health care. Here are the advantages they have, and the challenges they face.

New research finds patients with HIV and chronic pain are aware that opioids are addictive, yet most don’t receive common addiction-prevention monitoring.

Catch up on this week's biggest headlines in FDA news.

The supplement included data from decade-long noninferiority PRECISION trial, which revealed safety data for using celecoxib in conjunction with aspirin.

If approved, REMOXY ER will be classified as a schedule II drug and would be subject to strict prescribing and dispensing rules.

This is the only long-acting local anesthetic to demonstrate significantly reduced postoperative pain and opioid use through 72 hours compared to bupivacaine solution for postoperative pain management.

Impel NeuroPharma will study the safety and tolerability of dihydroergotamine delivered through the company’s Precision Olfactory Delivery device.

Researchers identified 6 types of potentially inappropriate prescriptions, all of which were associated with higher hazards for all-cause mortality, 4 with non-fatal overdose, and 5 with fatal overdose.

Researchers found nonfatal opioid overdose survivors have a 20-fold greater mortality rate in the months following their incident. However, designated therapies for such patients have been proven to counter that risk.

New immigration policies are affecting the health of thousands of migrant children, and physicians want the world to know about it.

Although there were no concerns regarding the safety profile of the CGRP inhibitor, the reduction in cluster headache attacks from baseline over the 12-week treatment period was underwhelming.

The buprenorphine and naloxone sublingual film is approved for the treatment of opioid abuse disorder in combination with counseling and psychosocial support.

The wearable device, Drug Relief, is a non-narcotic option for treatment and eases withdrawal symptoms within just 30-60 minutes.

The oral treatment was safe and efficacious over the course of a 12-week treatment period.

The guidelines included indications and contraindications, evidence supporting its use, and the use of nonparenteral forms of ketamine.

Gun violence is an epidemic in the US, but research remains underfunded compared to other leading causes of mortality.